Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07712107

A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model

This study is a multicenter, randomized controlled trial. The plan is to enroll eligible participants and randomly assign them to two groups: one group will undergo testing using a combined model of "multi-target blood methylation + fecal FIT + fecal calpetin"; those with positive results will immediately undergo standard gastrointestinal endoscopy, while those with negative results will enter routine observation; the other group will undergo only routine observation and follow-up. All enrolled participants will undergo a 5-year prospective follow-up, during which information on gastrointestinal cancer incidence and mortality will be collected through regular contact and review of medical records. The primary endpoint of the study is the difference in 5-year all-gastrointestinal cancer mortality between the two groups.This project aims to use a randomized controlled trial design to evaluate whether an active screening strategy based on a combined model can effectively reduce the population-level mortality from gastrointestinal cancers compared to routine surveillance. The objective is to provide high-level evidence for establishing a new screening strategy that reduces the disease burden and delivers public health benefits. It lays the foundation for validating novel biomarkers and exploring the biological and behavioral factors that influence screening outcomes, and offers clear decision-making support for optimizing China's comprehensive prevention and control system for gastrointestinal cancers.

Recruiting

Interested in participating?

Request Info

Key information

Age range

45 year–74 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gaoyao District People's Hospital, Zhaoqing City, Guangdong Province, Zhaoqing, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must be between 45 and 74 years of age at the time of enrollment;
  • Participants must agree to be randomly assigned to different screening and follow-up strategies;
  • Participants must agree to undergo a five-year follow-up in accordance with the protocol;
  • Participants must be willing to participate and sign an informed consent form.

Exclusion criteria

  • Underwent upper gastrointestinal endoscopy screening within the past year;
  • History of any type of malignant tumor;
  • Concurrent severe medical conditions that reduce the benefits of screening, such as severe pulmonary disease, kidney disease, liver disease, cardiovascular and cerebrovascular diseases, and hematological disorders;
  • Other situations where a physician determines that endoscopic screening poses excessive risk (e.g., hemodynamic instability) or offers no benefit (e.g., short life expectancy);
  • Pregnant or breastfeeding women.

Treatment and study plan

Multi-target blood methylation + fecal FIT + fecal calprotectin

Diagnostic Test

The intervention group underwent testing using a combined model of "multi-target blood methylation + fecal FIT + fecal calprotectin"; those with positive results subsequently underwent standard gastrointestinal endoscopy, while those with negative results were placed under routine observation.

Primary outcomes

  1. Differences in cancer-specific mortality rates across the entire gastrointestinal tract between the two groups.

    Time frame: Participants will be followed up for 5 years from the time of enrollment to collect data on gastrointestinal cancer-related deaths in both groups, with the final assessment of the primary outcome conducted at the 5-year mark after enrollment.

Secondary outcomes

  1. The incidence of gastrointestinal cancer in the two groups

    Time frame: Comparison of the incidence of new gastrointestinal cancers among the two groups of participants within five years of enrollment

  2. Sensitivity and specificity of the combined screening model for detecting gastrointestinal cancers in the intervention group

    Time frame: Baseline

  3. All-cause mortality in the two groups

    Time frame: All-cause mortality among all participants within 5 years of enrollment

  4. Detection rate of precancerous lesions and early-stage gastrointestinal tumors

    Time frame: At baseline and during foDetection of early-stage lesions llow-up within 5 years of enrollment

  5. Incidence of endoscopy-related complications

    Time frame: Incidence of various endoscopy-related complications observed within 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

Yongzhan Nie

CONTACT

[email protected]

+86 198 2975 8242

Sponsors and collaborators

Lead sponsor

Xijing Hospital

Other

Collaborators

  • First People's Hospital of Zhaoqing
  • Gansu Wuwei Tumor Hospital
  • The 960th Hospital of PLA
  • Wuxi People's Hospital
  • Yanting County Tumor Hospital
  • Zhaoqing Gaoyao People's Hospital

Registry information

Official study title

A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model: A Multi-center Prospective Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2035
Study completion
2035
First posted
Jul 17, 2026
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.